Continuing medical education during COVID-19: virtual training for gynecologic oncology management in Rwanda

Callie Weber, Seattle, USA; Diomede Ntasumbumuyange, Kigali, Rwanda; Eugene Ngoga, Kigali, Rwanda; Lisa Bazzett-Matabele, Gaborone, Botswana; Julie Francis, Oshawa, Canada; Pam Paley, Bellevue, USA; Katy Graef, Seattle, USA and Rahel Ghebre, Minneapolis, USA

Rwanda, a landlocked country in sub-Saharan Africa with a population of 12.3 million, is investing in cancer control and prioritizing the response to its highest-incidence cancers.1 2 Over 1500 Rwandan women develop gynecologic cancers each year, with 71% of those women dying from their disease.3 4

The Rwanda Biomedical Centre (RBC)—the implementation arm of the Ministry of Health—has prioritized the expansion of quality gynecologic cancer prevention, screening, diagnostic, and treatment services nationwide. As community-based cervical cancer screening programs are scaled, there is a need to build Rwanda’s capacity to manage all newly-identified cancer patients. Like many countries in sub-Saharan Africa, there are currently no specialized gynecologic-oncologists or established gynecologic-oncology training programs in Rwanda. Instead, the burden of care falls on general obstetrician-gynecologists (OB-GYNs).

Through its African Access Initiative,5 BIO Ventures for Global Health (BVGH, a non-profit organization based in Seattle, Washington) partnered with RBC in 2017 to improve cancer patient outcomes in Rwanda. In response to Rwandan OB-GYNs’ need for improved in-service oncology management training and continuing education during the COVID-19 pandemic, BVGH, RBC, and Rwandan and international academic partners designed and held an innovative, multi-week gynecologic cancer management training program targeting Rwanda’s OB-GYNs.

The training program covered the most prevalent gynecologic malignancies in Rwanda (Figure 1) and consisted of seven, 90 min live video lectures. Responses to a pre-course survey, as well as feedback received throughout the course, were used to refine the weekly content to the Rwandan OB-GYN’s needs. Each webinar featured case-based discussion groups delivered by one or two expert gynecologist-oncologists or oncologists from Botswana, Canada, Rwanda, or the USA. Faculty from the Rwandan Society of OB-GYN and the

Figure 1 Virtual training program weekly webinar topics and implementation team. The topics were identified and prioritized by Rwandan partners. The trainer(s) covered the role of Rwandan OB-GYNs in the screening, diagnosis, treatment, and referral of each cancer type and provided up-to-date information on current gynecology-oncology practices.

Figure 2 Geographic distribution of course participants.
University of Rwanda OB-GYN department guided course development and recruited 44 OB-GYNs from 18 Rwandan healthcare facilities to attend the course (Figure 2). Participants who completed all course materials received 21 continuing professional development credits from the Rwandan Medical and Dental Council.

Participants’ learning was measured via weekly homework assignments consisting of three to six multiple-choice and short-answer questions and identical pre- and post-course assessments. Following the webinar series, approximately half (51%) of the participants had improved their assessment scores by an average of 3%; however, this change was not statistically significant (Figure 3). The trainees were overwhelmingly satisfied with the course, with 98.3% of survey respondents indicating their plan to apply what they learned from the course to their daily work. Participants noted the minimal one-on-one mentorship and lack of hands-on opportunities as limitations of the course.

The results of this course demonstrate that virtual training—customized to the local setting—is feasible and highly acceptable to healthcare providers, yet does not replace the need for formal training of gynecologist-oncologists. As demonstrated by the statistically-insignificant increase in assessment scores, further training activities that build on the virtual program’s key learning points are needed to have a more substantial impact on OB-GYNs’ knowledge and their resulting management of gynecologic cancer patients. With these caveats in mind, the virtual training model can be extended to healthcare providers in other aspects of oncology and beyond.

**Correspondence to** Dr Katy Graef, BIO Ventures for Global Health, Seattle, Washington, USA; kgraef@bvgh.org

**Acknowledgements** The authors would like to thank Dr Kenneth Ruzindana (Kigali University Teaching Hospital), Dr Eugene Ngabonziza (Butaré University Teaching Hospital), and Dr Theodmir Sebazungu (University of Rwanda) for their support of the program and the participants. Thank you to course trainers: Mr Marc Hagenimana (Rwanda Biomedical Centre), and Dr Fidel Rubagumya (Rwanda Military Hospital). Thank you to colleagues at the Rwandan Medical and Dental Council for reviewing course materials and administering continuing professional development credits to graduates. Special thanks to Dr Princess Nothenba Simelela (WHO) for giving the keynote address during the course’s graduation ceremony.

**Contributors** Acknowledgements: The authors would like to thank Dr Kenneth Ruzindana (Kigali University Teaching Hospital), Dr Eugene Ngabonziza (Butaré University Teaching Hospital), and Dr Theodmir Sebazungu (University of Rwanda) for their support of the program and the participants. Thank you to course trainers: Mr Marc Hagenimana (Rwanda Biomedical Centre), and Dr Fidel Rubagumya (Rwanda Military Hospital). Thank you to colleagues at the Rwandan Medical and Dental Council for reviewing course materials and administering continuing professional development credits to graduates. Special thanks to Dr Princess Nothenba Simelela (WHO) for giving the keynote address during the course’s graduation ceremony.

**Funding** Merck & Co., Inc. (MSD).

**Competing interests** None declared.

**Provenance and peer review** Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.

do:10.1136/ijgc-2021-002476

Accepted 12 February 2021
Int J Gynecol Cancer 2021;0:1–2.
do:10.1136/ijgc-2021-002476

**ORCID iD**
Calie Weber http://orcid.org/0000-0001-7481-1306

**REFERENCES**


